Obstetrics and Gynecology Drugs Market Size Worth $25.28 Billion by 2030: The Brainy Insights

A growing geriatric female population and revitalized economic growth are likely to contribute to the growth of obstetrics and gynaecology drugs. North America emerged as the largest market for the global obstetrics and gynaecology drugs market, with a 36.92% share of the market revenue in 2022.

Newark, Jan. 09, 2023 (GLOBE NEWSWIRE) — The brainy Insights estimates that the USD 14.07 billion in 2022 Obstetrics and Gynaecology Drugs market will reach USD 25.28 billion by 2030. The rising incidences of various gynaecological cancer are expected to drive the market’s growth. Furthermore, the rise in the number of women suffering from ovarian cancer also adds to the market’s growth.

Download Report Sample (230+ Pages PDF with Insights) at: https://www.thebrainyinsights.com/enquiry/sample-request/13131

Key Insight of the Obstetrics and Gynaecology Drugs Market

North America to account for the largest market size during the forecast period.

North America is expected to have the largest obstetrics and gynaecology drugs market share. Key factors favouring the growth of the obstetrics and gynaecology drugs market in North America are the region’s increasing research and development activities. Furthermore, the presence of prominent market players in the region also adds to the market’s growth. In addition, the growing prevalence of menopausal problems, polycystic ovary syndrome, and other conditions among women in the region due to stressful lifestyles and busy schedules adds impetus to the market’s growth.

The non-hormonal therapy segment is expected to augment the obstetrics and gynaecology drugs market during the forecast period.

The non-hormonal therapy segment is anticipated to dominate the market over the forecast period. Non-hormonal therapy is proven efficient in obstetrics and gynaecology treatment and has reduced side effects propelling the segment’s growth.

The gynaecology infections segment market size is 3.65 billion in 2022

The gynaecology infections segment held the largest market share in 2022 and is expected to continue during the forecast period. The segment’s growth can be attributed to the increasing use of obstetrics and gynaecology drugs for the treatment of gynaecology treatment.

The hospital pharmacies segment is expected to augment the obstetrics and gynaecology drugs market during the forecast period.

The hospital pharmacies segment is anticipated to dominate the market over the forecast period. The growth of the hospital pharmacies segment is anticipated to be growing as most of the patients take the drugs after the doctor’s prescription and tend to purchase them from the hospital pharmacy, adding impetus to the segment’s growth.

Inquiry Before Buying: https://www.thebrainyinsights.com/enquiry/buying-inquiry/13131

Advancement in market

In January 2020, the gynaecological business in India and Nepal of India-based Glenmark Pharmaceuticals Ltd. was purchased by True North, a capital market company, for $16.2 million (INR 115 crore). By making this transaction, True North hopes to increase Glenmark’s gynaecological offerings and broaden its geographic reach.

In May 2021, The United States Food and Drug Administration (FDA) gave the thumbs-up to Myovant Sciences and Pfizer Inc.’s MYFEMBREE, the first once-daily medication for managing heavy menstrual bleeding linked to uterine fibroids in premenopausal women, with a treatment duration of up to 24 months.

Market Dynamics

Driver: Rising prevalence of cancer

The rising prevalence of ovarian cancer is expected to drive the market’s growth. There is an increase in ovarian cancer and gynaecological problems among women of all age groups. In addition, most women face issues related to childbirth which adds to the growth of Obstetrics and Gynaecology Drugs. Several women face menstrual problems due to the changing environment and lifestyle and go through early menopause. This also adds to the growth of the market.

Restraint: High Cost

The high cost of obstetrics and gynaecology drugs is hindering the market’s growth. Because of the high cost of these drugs, most patients cannot afford them. Most families from growing economies hesitate to go to hospitals as they cannot take up costly treatments and drugs, restraining the market’s growth.

Opportunity: Increasing awareness

These days, women are becoming more aware of their health conditions and taking good care of their health. With the minimum symptoms, they tend to check with a doctor and get themself tested for any diseases. Furthermore, the increasing annual income of families also helps take good care of women’s health. This is expected to provide growth opportunities for the market during the forecast period.

Challenge: Stringent regulatory framework

Several factors are expected to challenge the market growth, including the availability of stringent regulatory framework that delays drug approval. Furthermore, stringent government regulations also restrict drug use and sale due to their long-term effects on the human body.

Browse the full report with Table of Contents and List of Figures: https://www.thebrainyinsights.com/report/obstetrics-and-gynecology-drugs-market-13131

Some of the major players operating in the obstetrics and gynaecology drugs market are:

Key Segments cover in the market:

● Lupin Limited
● Bayer AG
● Pfizer, Inc
● Eli Lily and Company, Ltd.
● AbbVie, Inc.
● Ferring B.V.
● Johnson & Johnson
● AstraZeneca
● Merck & Co., Inc.
● Hoffman-La Roche, Ltd.
● GlaxoSmithKline plc
● Abbott
● Novartis AG
● Amgen, Inc.

By Type:

● Non-Hormonal Therapy
● Hormonal Therapy

By Application:

● Female Infertility
● Contraception
● Postmenopausal Disorders
● Gynaecology Infections
● Endometriosis
● Others

By Distribution Channel:

● Online Pharmacies
● Hospital Pharmacies
● Retail Pharmacies

By Region

● North America (U.S., Canada, Mexico)
● Europe (Germany, France, the U.K., Italy, Spain, Rest of Europe)
● Asia-Pacific (China, Japan, India, Rest of APAC)
● South America (Brazil and the Rest of South America)
● The Middle East and Africa (UAE, South Africa, Rest of MEA)

Inquire for Customized Data: https://www.thebrainyinsights.com/enquiry/request-customization/13131

About the report:

The market is analyzed based on value (USD Billion). All the segments have been analyzed worldwide, regional, and country basis. The study includes the analysis of more than 30 countries for each part. The report analyzes driving factors, opportunities, restraints, and challenges for gaining critical insight into the market. The study includes porter’s five forces model, attractiveness analysis, Product analysis, supply, and demand analysis, competitor position grid analysis, distribution, and marketing channels analysis.

About The Brainy Insights:

The Brainy Insights is a market research company that provides actionable insights through data analytics to companies to improve their business acumen. They have a robust forecasting and estimation model to meet the client’s objectives of high-quality output within a short period. They provide both customized (client-specific) and syndicate reports. Their repository of syndicate reports is diverse across all the categories and sub-categories across domains. Their customized solutions meet the client’s requirements whether they are looking to expand or planning to launch a new product in the global market.

Contact Us

Avinash D
Head of Business Development
Phone: +1-315-215-1633
Email: [email protected] 
Web: http://www.thebrainyinsights.com

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaChron.com takes no editorial responsibility for the same.